BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Jason Kelce opens about wife Kylie Kelce's past pregnancy loss - 2Taste the World: Five Food sources That Have Dazzled Worldwide Palates
- 3An 'explosion' of solo-agers are struggling with rising costs and little support: 'I'm flying without a net'
- 4The Main 15 Powerful Business Heads of Today
- 5Which Espresso Do You Like Best? Vote
- The Following Huge Thing: 5 Progressive Tech New businesses
- Most loved Occasion Dish: What Makes Your Merry Table?
- 2024 Moving Styles for Kitchen Redesigns
- The Golden Globes is happening Sunday: Who's nominated, who's hosting and how to watch
- As her kidneys fail and time runs short, this activist fights to decriminalize euthanasia in Mexico
- Flu surges across U.S. as doctor visits reach highest level since 1997
- Nestlé recalls infant formula in 49 countries. See list.
- Climbing Mount Everest: An Individual Victory
- Humpback whale freed by rescuers in Baltic Sea has become stranded again
